Major Inclusion Criteria for Recurrent GBM Patients:

          1. Age 18 or older;

          2. Histologically confirmed GBM (glioblastoma), WHO Grade 4;

          3. Patients must have a Karnofsky Performance Status (KPS) ≥70 or Eastern Cooperative
             Oncology Group (ECOG) performance status of 0-2 (see Appendix 7);

          4. Previously received standard front-line GBM treatment including maximal surgical
             resection followed by external beam radiation therapy and TMZ therapy. Prior use of
             NovoTTF (Optune) and Gliadel wafers is allowed;

          5. Patients must be in first relapse;

               1. Relapse is defined as progression following initial therapy (i.e., radiation
                  and/or chemotherapy). The intent therefore is that patients had no more than 1
                  prior therapy (i.e., initial treatment). If the patient had a surgical resection
                  for relapsed disease and no anti-cancer therapy was instituted for up to 12
                  weeks, and the patient undergoes another surgical resection, this is considered
                  to constitute one (1) relapse;

               2. Documented recurrence or progression by brain MRI imaging ≤14 days before study
                  registration;

               3. Measurable disease by RANO criteria (≥ 10 mm x 10 mm).

        Major Inclusion criteria for newly diagnosed patients:

          1. Ages 18 or older;

          2. Newly diagnosed glioblastoma or gliosarcoma (WHO Grade 4) confirmed by histology or
             astrocytomas with molecular features of gliobastoma;

          3. Starting maintenance therapy with temozolomide (150 mg/m^2 on Days 1-5 every 28 days)
             within 4 weeks prior to screening phase;

          4. If patient is receiving corticosteroid, dose must be stable or decreasing for at least
             5 days prior to the scan. If steroids are added or the steroid dose is increased
             between the date of the pretreatment MRI and the start of study, a new baseline MRI or
             CT scan is required;

          5. Karnofsky Performance Status ≥60 at time of screening;

          6. ECOG score of 0 or 1 at time of screening;

          7. Life expectancy of at least 3 months.

        Exclusion Criteria (applied to all patients):

          1. History of Grade 2 (CTCAE v4.0) or greater intracranial or intratumoral hemorrhage
             confirmed by either MRI or CT scan;

          2. Current use of anticoagulant treatment with coumadin (low-molecular-weight heparin and
             factor Xa inhibitors are permitted);

          3. Any systemic illness or unstable medical condition that might pose additional risk,
             including: cardiac, unstable metabolic or endocrine disturbances, renal or liver
             disease;

          4. Patients with a history of a different malignancy except the following circumstances:

               1. They have been disease-free for at least 2 years prior to starting study drug and
                  are deemed by the investigator to be at low risk for recurrence of that
                  malignancy. Patients with the following cancers are eligible if diagnosed and
                  treated within the past 2 years: i. Cervical cancer in situ, and basal cell or
                  squamous cell carcinoma of the skin;

        7) Patients who have not recovered to ≤ Grade 1 toxicity by NCI CTCAE v4.0 from the toxic
        effects of previous therapy with exception of lymphopenia, alopecia and fatigue; 9) For use
        of other investigational drug or other anti-tumor treatment, the following time periods
        must have elapsed from the projected start of scheduled study treatment:

          1. 4 weeks or 5 half-lives (whichever is shorter) from any investigational agent;

          2. 4 weeks from cytotoxic therapy (except 23 days for TMZ; 6 weeks from nitrosoureas);

          3. 6 weeks from antibodies treatment (i.e., anti-VEGF antibody);

          4. 4 weeks or 5 half-lives (whichever is shorter) from other anti-tumor therapies;

          5. 2 days from NOVO-TTF (Optune®).